Evidence map›Paper›PMID 19006606›Full record

ReviewCurrent gastroenterology reports2008

Pharmacology of proton pump inhibitors.

Jai Moo Shin, George Sachs

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current gastroenterology reports, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 213 papers, 14 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
213citing papers in PubMed, 14 pooled it
6.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

213 citing papers in PubMed, 14 syntheses or guidelines pooled it, 524 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Guideline
  12. Pooled it
  13. Proton pump inhibitor use is associated with increased risk of severity and mortality from coronavirus disease 2019 (COVID-19) infection.Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · 2020
    Pooled it
  14. Pooled it
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

153 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Jai Moo ShinMembrane Biology, David Geffen School of Medicine, University of California at Los Angeles, Room 324, Building 113, 11301 Wilshire Boulevard, Los Angeles, CA 90073, USA.
George Sachs
University of California, Los Angeles · US

Funding

The Gastric Biology of Helicobacter PyloriR01DK053642 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SACHS, GEORGE · 1997 to 2012
$3.2M
THE GASTRIC ACID PUMP AS A TARGET FOR ULCER TREATMENTR01DK058333 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SACHS, GEORGE · 2000 to 2009
$2.6M
The Gastric Acid Pump as a Target for Ulcer TreatmentR56DK058333 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SACHS, GEORGE · 2010 to 2010
$229k
NIDDK NIH HHS DK053642NIDDK NIH HHS DK58333NIDDK NIH HHS R01 DK053642NIDDK NIH HHS R01 DK058333NIDDK NIH HHS R56 DK058333
6 · The paper itself

Abstract

The gastric H,K-ATPase is the primary target for the treatment of acid-related diseases. Proton pump inhibitors (PPIs) are weak bases composed of two moieties, a substituted pyridine with a primary pK(a) of about 4.0, which allows selective accumulation in the secretory canaliculus of the parietal cell, and a benzimidazole with a second pK(a) of about 1.0. PPIs are acid-activated prodrugs that convert to sulfenic acids or sulfenamides that react covalently with one or more cysteines accessible from the luminal surface of the ATPase. Because of covalent binding, their inhibitory effects last much longer than their plasma half-life. However, the short half-life of the drug in the blood and the requirement for acid activation impair their efficacy in acid suppression, particularly at night. PPIs with longer half-life promise to improve acid suppression. All PPIs give excellent healing of peptic ulcers and produce good results in reflux esophagitis. PPIs combined with antibiotics eradicate Helicobacter pylori.

Indexed as

AnimalsAntacidsAnti-Ulcer AgentsEsophagitisGastric AcidGastroesophageal RefluxHumansParietal Cells, GastricPeptic UlcerProton Pump InhibitorsAntacidsAnti-Ulcer AgentsProton Pump Inhibitors

Identifiers

PMID19006606
PMCPMC2855237
OpenAlexW2064517127

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.